[go: up one dir, main page]

PE20091307A1 - Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica

Info

Publication number
PE20091307A1
PE20091307A1 PE2009000067A PE2009000067A PE20091307A1 PE 20091307 A1 PE20091307 A1 PE 20091307A1 PE 2009000067 A PE2009000067 A PE 2009000067A PE 2009000067 A PE2009000067 A PE 2009000067A PE 20091307 A1 PE20091307 A1 PE 20091307A1
Authority
PE
Peru
Prior art keywords
carboxamides
indol
azaindol
substituted
group
Prior art date
Application number
PE2009000067A
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Andre Malanda
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20091307A1 publication Critical patent/PE20091307A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE INDOL 2-CARBOXAMIDAS Y DE AZAINDOL 2-CARBOXAMIDAS SUSTITUIDOS CON UN GRUPO SILANILO DE FORMULA (I) DONDE G1, G2, G3 Y G4 SON CADA UNO C-X O N, EN DONDE X ES H, HALOGENO, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; Y ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS CON HALOGENO, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ENTRE OTROS SUSTITUYENTES; Z1, Z2, Z3 Y Z4 SON CADA UNO N O C(R6), DONDE R6 ES H, HALOGENO, ALCOXILO(C1-C6), ENTRE OTROS; Z ES UNA AMINA CICLICA DE FORMULA (a), EN DONDE A ES ALQUILENO(C1-C7) OPCIONALMENTE SUSTITUIDO CON R8; B ES ALQUILENO(C1-C7) OPCIONALMENTE SUSTITUIDO CON R9; L ES UN ENLACE, O, S O N; R8 Y R9 FORMAN UN ENLACE O ALQUILENO(C1-C6); n ES DE 0 A 3. SON COMPUESTOS PREFERIDOS: N-[6-(AZETIDIN-1-IL)PIRIDIN-3-IL]-6-TRIMETILSILIL-1-[(3-FLUOROFENIL)METIL]-1-H-INDOL-2-CARBOXAMIDA, N-[6-(3-HIDROXIAZETIDIN-1-IL)PIRIDIN-3-IL]-6-TRIMETILSILIL-1-[(3-FLUOROFENIL)METIL]-1H-INDOL-2-CARBOXAMIDA, N-[6-(AZETIDIN-1-IL)PIRIDIN-3-IL]-5-TRIMETILSILIL-1-[(3-FLUOROFENIL)METIL]-1-H-INDOL-2-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE TIPO TRPV1 (VR1) SIENDO UTILES EN EL TRATAMIENTO DE HIPERACTIVIDAD DE LA VEJIGA, INCONTINENCIA, DISMENORREAS, ULCERA DE ESTOMAGO
PE2009000067A 2008-01-23 2009-01-21 Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica PE20091307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0800343A FR2926553B1 (fr) 2008-01-23 2008-01-23 Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20091307A1 true PE20091307A1 (es) 2009-09-21

Family

ID=39671700

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000067A PE20091307A1 (es) 2008-01-23 2009-01-21 Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica

Country Status (23)

Country Link
US (1) US8399491B2 (es)
EP (1) EP2235003B1 (es)
JP (1) JP5508287B2 (es)
KR (1) KR20100115358A (es)
CN (1) CN102143956B (es)
AR (1) AR070214A1 (es)
AU (1) AU2009221032B2 (es)
BR (1) BRPI0906634A2 (es)
CA (1) CA2712921C (es)
CL (1) CL2009000127A1 (es)
CO (1) CO6220974A2 (es)
EA (1) EA201070874A1 (es)
FR (1) FR2926553B1 (es)
IL (1) IL207079A0 (es)
MA (1) MA32087B1 (es)
MX (1) MX2010008101A (es)
MY (1) MY150289A (es)
NZ (1) NZ586964A (es)
PE (1) PE20091307A1 (es)
TW (1) TW200936578A (es)
UY (1) UY31612A1 (es)
WO (1) WO2009109710A1 (es)
ZA (1) ZA201005242B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
EA026368B1 (ru) 2011-12-21 2017-03-31 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
SG11201501359TA (en) 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
JP6441315B2 (ja) 2013-05-17 2018-12-19 ヤンセン・サイエンシズ・アイルランド・ユーシー スルファモイルチオフェンアミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
DK3024819T3 (en) 2013-07-25 2018-06-06 Janssen Sciences Ireland Uc GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
AU2014338947B2 (en) 2013-10-23 2018-02-22 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (ko) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Hbv 감염의 치료를 위한 병용 요법
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
CN107847762A (zh) 2015-03-19 2018-03-27 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
RS62639B1 (sr) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitori histonskih deacetilaza
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
CN105820104B (zh) * 2016-03-10 2018-12-11 温州医科大学 一种具有抗炎作用的吲哚-2-酰胺类化合物及其在制备抗炎药物中的应用
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
TWI770104B (zh) 2017-01-11 2022-07-11 美商羅登醫療公司 組蛋白去乙醯酶雙環抑制劑
PL3664802T3 (pl) 2017-08-07 2022-07-11 Alkermes, Inc. Bicykliczne inhibitory deacetylaz histonowych
EP3765011A1 (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
AU2019203034B1 (en) 2018-07-25 2019-09-26 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
PE20212153A1 (es) 2019-02-22 2021-11-09 Hanmi Pharm Ind Co Ltd Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda
EP3966205A1 (en) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
WO2020262974A1 (ko) 2019-06-27 2020-12-30 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316777T3 (es) * 2002-02-15 2009-04-16 Glaxo Group Limited Moduladores de receptores vainilloides.
US7338950B2 (en) * 2003-10-07 2008-03-04 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
WO2005072681A2 (en) * 2004-01-23 2005-08-11 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain.
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
FR2897061B1 (fr) * 2006-02-03 2010-09-03 Sanofi Aventis Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique.
FR2903985B1 (fr) * 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) * 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
FR2910473B1 (fr) * 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
EA201070874A1 (ru) 2011-02-28
CN102143956B (zh) 2014-04-23
MA32087B1 (fr) 2011-02-01
ZA201005242B (en) 2011-09-28
MY150289A (en) 2013-12-31
AU2009221032B2 (en) 2013-09-26
JP5508287B2 (ja) 2014-05-28
CL2009000127A1 (es) 2010-02-12
CN102143956A (zh) 2011-08-03
KR20100115358A (ko) 2010-10-27
JP2011510052A (ja) 2011-03-31
TW200936578A (en) 2009-09-01
EP2235003A1 (fr) 2010-10-06
EP2235003B1 (fr) 2012-12-19
CA2712921A1 (fr) 2009-09-11
IL207079A0 (en) 2010-12-30
US20110009365A1 (en) 2011-01-13
NZ586964A (en) 2012-06-29
FR2926553B1 (fr) 2010-02-19
WO2009109710A1 (fr) 2009-09-11
MX2010008101A (es) 2010-08-04
UY31612A1 (es) 2009-08-31
AR070214A1 (es) 2010-03-25
BRPI0906634A2 (pt) 2015-07-14
CA2712921C (fr) 2016-08-02
US8399491B2 (en) 2013-03-19
AU2009221032A1 (en) 2009-09-11
CO6220974A2 (es) 2010-11-19
FR2926553A1 (fr) 2009-07-24

Similar Documents

Publication Publication Date Title
PE20091307A1 (es) Derivados de indol 2-carboxamidas y de azaindol 2-carboxamidas sustituidos con un grupo silanilo, su preparacion y su aplicacion en terapeutica
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
PE20090876A1 (es) Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet
PE20071171A1 (es) Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropicos
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20080688A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de trpv1 y su preparacion
PE20070112A1 (es) Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20120061A1 (es) Derivados de pirimidina como antagonistas del receptor ccr2
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
CR10236A (es) Modulares del indol sulfonamida de receptores de progesterona
PE20090900A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
PH12012501535A1 (en) Substituted naphthyridines and their use as syk kinase inhibitors
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20140610A1 (es) Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
AR070352A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k, un procedimiento de elaboracion del compuesto, una composicion farmaceutica y un agente preventivo o terapeutico en base al compuesto.
PE20091350A1 (es) Derivados de sulfonamidas sustituidas
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20091649A1 (es) Derivados de pirrolidinilo

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed